Overview
In recent years, novel synthetic opioids (NSOs) have been detected in drug seizures and in biological samples in the United Kingdom. These compounds are highly potent, and so keeping current with which compounds are in circulation in the illicit drug market in the UK, and how best to detect them in a range of samples is important to inform public health decisions, and to minimise the risk of false negative analyses. This webinar will discuss the analytical considerations for maximising detection of a range of these compounds, including how to attempt to keep ahead of newly-emerging analogues.
This event will take place at 1:00pm and last approximately 1 hour.
CPD
This meeting is worth 1 CPD point (self credited).
Analytical considerations for detecting and quantifying novel synthetic opioids, including ‘nitazenes’, in biological samples
-
Dr Lewis Couchman
Lewis is currently the Facility & Research Director at Analytical Services International, based at St Georges, University of London. His current role involves overseeing the development, implementation, and routine analysis of biological samples for TDM, forensic and clinical toxicology, and for the support of clinical trials. Lewis completed his BSc degree at Loughborough University, his MSc and Clinical Scientist Training courses at Queen Mary University of London and King’s College Hospital, and his PhD at the University of Leicester. Additionally, Lewis is a committee member of the Royal Society of Chemistry Separation Science Group and London Biological Mass Spectrometry Discussion Group, and the past Chair of the London Toxicology Group.
-
Dr Atholl Johnston
Webinar Chair
